Use of levetiracetam for the successful treatment of suspected myoclonic seizures: five dogs (2016-2022).
Journal
The Journal of small animal practice
ISSN: 1748-5827
Titre abrégé: J Small Anim Pract
Pays: England
ID NLM: 0165053
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
revised:
11
10
2023
received:
28
06
2023
accepted:
07
02
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
aheadofprint
Résumé
Myoclonic seizures are considered a type of generalised seizure characterised by brief, jerking movements of the body. The aim of this study is to describe cases of suspected canine myoclonic seizure of idiopathic aetiology and to discuss the successful use of the anticonvulsant levetiracetam as treatment in each of these cases. Dogs with epileptic myoclonus suspected to be idiopathic in aetiology were considered for inclusion. Medical records were reviewed for physical and neurologic examination findings, clinicopathologic results, and diagnostic imaging results. All included dogs were treated with levetiracetam, and their response was reported. Five dogs were included, all of which had suspected myoclonic seizures either observed in-person or on video recording by a board-certified veterinary neurologist. The duration of myoclonic seizures preceding treatment ranged from one day to one year. One dog also experienced a generalised tonic-clonic seizure. All dogs were treated with levetiracetam. Two dogs experienced long-term myoclonic seizure freedom (duration seizure-free of at least 1 year), and two dogs experienced marked decreased myoclonic seizure frequency. One dog experienced immediate abatement of myoclonic seizures, although levetiracetam was only utilised for 1 month following onset of myoclonic seizures in this patient. Myoclonic seizures can be idiopathic in aetiology. Levetiracetam can be used effectively to rapidly stop myoclonic seizures and to decrease the frequency of myoclonic seizures.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Journal of Small Animal Practice published by John Wiley & Sons Ltd on behalf of British Small Animal Veterinary Association.
Références
Abu‐Hegazy, M., Elmoungi, A., Eltantawi, E. & Esmael, A. (2021) Electrophysiological characteristics and anatomical differentiation of epileptic and non‐epileptic myoclonus. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 57, 124.
Beasley, M.J. & Boothe, D.M. (2015) Disposition of extended release levetiracetam in normal healthy dogs after single oral dosing. Journal of Veterinary Internal Medicine, 29, 1348–1353.
Berendt, M., Farquhar, R.G., Mandigers, P.J.J., Pakozdy, A., Bhatti, S.F.M., de Risio, L. et al. (2015) International veterinary epilepsy task force consensus report on epilepsy definition, classification, and terminology in companion animals. BMC Veterinary Research, 11, 182.
Chambers, J.K., Thontharb, A., Shiga, T., Azakami, D., Saito, M., Sato, M. et al. (2018) Accumulation of Laforin and other related proteins in canine Lafora disease with EPM2B repeat expansion. Veterinary Pathology, 55, 543–551.
Chapman, D., Korff, C.P. & Davies, E. (2022) What is your neurologic diagnosis? Journal of the American Veterinary Medical Association, 260, 1784–1786.
Fisher, R.S., Cross, J.H., French, J.A., Higurashi, N., Hirsch, E., Jansen, F.E. et al. (2017) Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 58, 522–530.
Flegel, T., Kornberg, M., Mühlhause, F., Neumann, S., Fischer, A., Wielaender, F. et al. (2021) A retrospective case series of clinical signs in 28 beagles with Lafora disease. Journal of Veterinary Internal Medicine, 35, 2359–2365.
Fredso, N., Sabers, A., Toft, N., Moller, A. & Berendt, M. (2016) A single‐blinded phenobarbital‐controlled trial of levetiracetam as monotherapy in dogs with newly diagnosed epilepsy. The Veterinary Journal, 208, 44–49.
Heske, L., Nødtvedt, A., Hultin Jäderlund, K., Berendt, M. & Egenvall, A. (2014) A cohort study of epilepsy among 665,000 insured dogs: incidence, mortality and survival after diagnosis. Veterinary Journal, 202, 471–476.
Kearsley‐Flee, L., O'Neill, D.G., Volk, H.A., Church, D.B. & Brodbelt, D.C. (2013) Prevalence and risk factors for canine epilepsy of unknown origin in the UK. The Veterinary Record, 172, 338.
Kelly, D., Raimondi, F. & Shihab, N. (2017) Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010‐2015). The Veterinary Record, 181, 401–407.
Labate, A., Colosimo, E., Gambardella, A., Leggio, U., Ambrosio, R. & Quattrone, A. (2006) Levetiracetam in patients with generalized epilepsy and myoclonic seizures: an open label study. Seizure, 15, 214–218.
Lowrie, M. & Garosi, L. (2017) Classification of involuntary movements in dogs: myoclonus and myotonia. Journal of Veterinary Internal Medicine, 31, 979–987.
Lowrie, M., Thomson, S., Bessant, C., Sparkes, A., Harvey, R.J. & Garosi, L. (2017) Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open‐label study. Journal of Feline Medicine and Surgery, 19, 200–206.
Lowrie, M., Garosi, L. (2017) Classification of Involuntary Movements in Dogs: Myoclonus and Myotonia. Journal of Veterinary Internal Medicine, 31, 979–987.
Lynch, B.A., Lambeng, N., Nocka, K., Kensel‐Hammes, P., Bajjalieh, S.M., Matagne, A. et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America, 101, 9861–9866.
Malykh, A.G. & Reza Sadaie, M. (2010) Piracetam and piracetam‐like drugs from basic science to novel clinical applications to CNS disorders. Drugs, 70, 287–312.
Noachtar, S., Andermann, E., Meyvisch, P., Andermann, F., Gough, W.B. & Schiemann‐Delgado, J. (2008) Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology, 70, 607–616.
Packer, R.M.A., Nye, G., Porter, S.E. & Volk, H.A. (2015) Assessment into the usage of levetiracetam in a canine epilepsy clinic. BMC Veterinary Research, 22, 1–8.
Podell, M., Volk, H.A., Berendt, M., Löscher, W., Muñana, K., Patterson, E.E. et al. (2016) 2015 ACVIM small animal consensus statement on seizure management in dogs. Journal of Veterinary Internal Medicine, 30, 477–490.
Potschka, H., Fischer, A., Löscher, W., Patterson, N., Bhatti, S., Berendt, M. et al. (2015) International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy. BMC Veterinary Research, 11, 177.
Rotter, C., Whittaker, D. & Rusbridge, C. (2022) Myoclonus in older cavalier king Charles spaniels. Journal of Veterinary Internal Medicine, 36, 1032–1038.
Sharpe, D.V., Patel, A.D., Abou‐Khalil, B. & Fenichel, G.M. (2008) Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure, 17, 64–68.
Wheless, J.W. & Sankar, R. (2003) Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia, 44, 27–37.
Wielaender, F., Sarviaho, R. & James, F. (2017) Generalized myoclonic epilepsy with photosensitivity in juvenile dogs caused by a defective DIRAS family GTPase 1. Proceedings of the National Academy of Sciences of the United States of America, 114, 2669–2674.
Wielaender, F., James, F.M.K., Cortez, M.A., Kluger, G., Neßler, J.N., Tipold, A. et al. (2018) Absence seizures as a feature of juvenile myoclonic epilepsy in Rhodesian Ridgeback dogs. Journal of Veterinary Internal Medicine, 31, 428–432.
Zifkin, B., Andermann, E. & Andermann, F. (2005) Mechanisms, genetics, and pathogenesis of juvenile myoclonic epilepsy. Current Opinion in Neurology, 18, 147–153.